{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:46:47Z","timestamp":1785545207604,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.14283\/jpad.2022.52","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T07:33:33Z","timestamp":1652340813000},"page":"469-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease"],"prefix":"10.1016","volume":"9","author":[{"given":"Simona","family":"Piccirella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Van Neste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Doecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Uberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2022.52_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","article-title":"On the path to 2025: understanding the Alzheimer's disease continuum","volume":"9","author":"Aisen","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.52_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.52_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.52_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.52_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.52_bib6","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","article-title":"Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease","volume":"25","author":"Buttini","year":"2005","journal-title":"J Neurosci"},{"key":"10.14283\/jpad.2022.52_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and Progress in Alzheimer's Disease \u2014 FDA Approval of Aducanumab","author":"Rabinovici","year":"2021","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.52_bib8","author":"Biogen Inc"},{"key":"10.14283\/jpad.2022.52_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-05542-4_2","article-title":"The role of biomarkers in Alzheimer's disease drug development","volume":"1118","author":"Cummings","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.14283\/jpad.2022.52_bib10","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2022.52_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2022.52_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2022.52_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cns.13050","article-title":"Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's disease?","volume":"25","author":"Merlo","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"10.14283\/jpad.2022.52_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-161088","article-title":"Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease","volume":"57","author":"Tonnies","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2022.52_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1567205013666161010125413","article-title":"Comparison of Extracellular and Intracellular Blood Compartments Highlights Redox Alterations in Alzheimer's and Mild Cognitive Impairment Patients","volume":"14","author":"Arce-Varas","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.14283\/jpad.2022.52_bib16","doi-asserted-by":"crossref","first-page":"e68361","DOI":"10.1371\/journal.pone.0068361","article-title":"Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer's disease [corrected]","volume":"8","author":"Katsel","year":"2013","journal-title":"PLoS One"},{"key":"10.14283\/jpad.2022.52_bib17","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1242\/jcs.115.15.3131","article-title":"Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients","volume":"115","author":"Uberti","year":"2002","journal-title":"J Cell Sci"},{"key":"10.14283\/jpad.2022.52_bib18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jnc.12154","article-title":"Zyxin is a novel target for beta-amyloid peptide: characterization of its role in Alzheimer's pathogenesis","volume":"125","author":"Lanni","year":"2013","journal-title":"J Neurochem"},{"key":"10.14283\/jpad.2022.52_bib19","doi-asserted-by":"crossref","first-page":"e10171","DOI":"10.1371\/journal.pone.0010171","article-title":"Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival","volume":"5","author":"Lanni","year":"2010","journal-title":"PLoS One"},{"key":"10.14283\/jpad.2022.52_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1471-4159.2007.04757.x","article-title":"Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin","volume":"103","author":"Uberti","year":"2007","journal-title":"J Neurochem"},{"key":"10.14283\/jpad.2022.52_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2174\/156720512804142886","article-title":"Searching for predictive blood biomarkers: misfolded p53 in mild cognitive impairment","volume":"9","author":"Stanga","year":"2012","journal-title":"Curr Alzheimer Res"},{"key":"10.14283\/jpad.2022.52_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2010-1347","article-title":"Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease","volume":"20","author":"Lanni","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2022.52_bib23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.mp.4002060","article-title":"Conformationally altered p53: a novel Alzheimer's disease marker?","volume":"13","author":"Lanni","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.14283\/jpad.2022.52_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11010014","article-title":"A conformation variant of p53 combined with machine learning identifies Alzheimer disease in preclinical and prodromal stages","volume":"11","author":"Abate","year":"2020","journal-title":"J Pers Med"},{"key":"10.14283\/jpad.2022.52_bib25","author":"Piccirella"},{"key":"10.14283\/jpad.2022.52_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/ADR-210005","article-title":"Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease","volume":"5","author":"Fowler","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"10.14283\/jpad.2022.52_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease","volume":"21","author":"Ellis","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"10.14283\/jpad.2022.52_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer's & Dementia"},{"key":"10.14283\/jpad.2022.52_bib29","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1212\/WNL.0b013e318211c352","article-title":"Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging","volume":"76","author":"Gupta","year":"2011","journal-title":"Neurology"},{"key":"10.14283\/jpad.2022.52_bib30","unstructured":"Memo M and Uberti DL. Antibody binding a linear epitope of human p53 and diagnostic applications thereof, 2018. EP3201234. November 7."},{"key":"10.14283\/jpad.2022.52_bib31","first-page":"6","article-title":"p53 Isoforms: Key regulators of the cell fate decision","author":"Joruiz","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.14283\/jpad.2022.52_bib32","doi-asserted-by":"crossref","first-page":"a000927","DOI":"10.1101\/cshperspect.a000927","article-title":"The isoforms of the p53 protein","volume":"2","author":"Khoury","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.14283\/jpad.2022.52_bib33","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and Comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Statistics in Medicine"},{"key":"10.14283\/jpad.2022.52_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.14283\/jpad.2022.52_bib35","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2020"},{"key":"10.14283\/jpad.2022.52_bib36","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v098.i11","article-title":"cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Softw"},{"key":"10.14283\/jpad.2022.52_bib37","first-page":"1","article-title":"Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia","volume":"5","author":"Horgan","year":"2020","journal-title":"Biomed Hub"},{"key":"10.14283\/jpad.2022.52_bib38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbcan.2018.06.001","article-title":"Control of metabolism by p53 \u2014 Cancer and beyond","volume":"1870","author":"Labuschagne","year":"2018","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.14283\/jpad.2022.52_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/acel.12335","article-title":"CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of beta-secretase","volume":"14","author":"Singh","year":"2015","journal-title":"Aging Cell"},{"key":"10.14283\/jpad.2022.52_bib40","doi-asserted-by":"crossref","first-page":"e99897","DOI":"10.1371\/journal.pone.0099897","article-title":"Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease","volume":"9","author":"Silva","year":"2014","journal-title":"PLoS One"},{"key":"10.14283\/jpad.2022.52_bib41","doi-asserted-by":"crossref","first-page":"18055","DOI":"10.1073\/pnas.1419083111","article-title":"p53 prevents neurodegeneration by regulating synaptic genes","volume":"111","author":"Merlo","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.14283\/jpad.2022.52_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/cdd.2008.175","article-title":"A p53-CBP\/p300 transcription module is required for GAP-43 expression, axon outgrowth, and regeneration","volume":"16","author":"Tedeschi","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.14283\/jpad.2022.52_bib43","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1038\/sj.emboj.7601292","article-title":"The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration","volume":"25","author":"Di Giovanni","year":"2006","journal-title":"EMBO J"},{"key":"10.14283\/jpad.2022.52_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.freeradbiomed.2008.03.015","article-title":"Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease","volume":"45","author":"Cenini","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.14283\/jpad.2022.52_bib45","doi-asserted-by":"crossref","first-page":"116064","DOI":"10.1016\/j.trac.2020.116064","article-title":"Conjugating immunoassays to mass spectrometry: solutions to contemporary challenges in clinical diagnostics","volume":"132","author":"Stevens","year":"2020","journal-title":"Trends Analyt Chem"},{"key":"10.14283\/jpad.2022.52_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40120-019-00165-4","article-title":"A review on MS-based blood biomarkers for Alzheimer's disease","volume":"8","author":"Oeckl","year":"2019","journal-title":"Neurol Ther"},{"key":"10.14283\/jpad.2022.52_bib47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1373\/clinchem.2015.248146","article-title":"Effective use of mass spectrometry in the clinical laboratory","volume":"62","author":"Jannetto","year":"2016","journal-title":"Clin Chem"},{"key":"10.14283\/jpad.2022.52_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1148\/radiol.12120010","article-title":"Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers","volume":"266","author":"Shaffer","year":"2013","journal-title":"Radiology"},{"key":"10.14283\/jpad.2022.52_bib49","first-page":"e12104","article-title":"Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia","volume":"12","author":"Shen","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.14283\/jpad.2022.52_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.14283\/jpad.2022.52_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13195-020-00738-8","article-title":"Amyloid-beta misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline","volume":"12","author":"Stockmann","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2022.52_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13195-019-0561-5","article-title":"PET and CSF amyloid-\u03b2 status are differently predicted by patient features: information from discordant cases","volume":"11","author":"Reimand","year":"2019","journal-title":"Alz Res Therapy"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724003054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:11:39Z","timestamp":1737321099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724003054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2274580724003054"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2022.52","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.23.21261848","asserted-by":"object"}]},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2022.52","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}